Difference between revisions of "User talk:Beno Marija/Pressrelease"
Beno Marija (talk | contribs) (Created page with "{{OROBOROS_header_page_name}} <div style="font-size:100%;font-weight:bold;padding:0.2em;padding-right: 0.4em;padding-left: 0.4em;background-color:#eeeeee;border-bottom:1px so...") |
Beno Marija (talk | contribs) |
||
| Line 1: | Line 1: | ||
<div style="padding:0px;border: 1px solid #aaaaaa;margin-bottom:0px;margin-right:10px;margin-top:20px;"> | |||
<div style="font-size:100%;font-weight:bold;padding:0.2em;padding-right: 0.4em;padding-left: 0.4em;background-color:#eeeeee;border-bottom:1px solid #aaaaaa;text-align:left;"> | <div style="font-size:100%;font-weight:bold;padding:0.2em;padding-right: 0.4em;padding-left: 0.4em;background-color:#eeeeee;border-bottom:1px solid #aaaaaa;text-align:left;"> | ||
[[Image:OROBOROS-solo.png|80px|right|link=Oroboros symbol |Oroboros symbol]] | |||
'''Oroboros News''' | |||
</div> | </div> | ||
<div style="background-color:#ffffff;padding-top:0.2em;padding-right: 0.4em;padding-bottom: 0.2em;padding-left: 0.4em;"> | |||
[[Image:MitoPedia.jpg|60px|link=http://www.bioblast.at/index.php/MitoPedia|MitoPedia]] '''''New in'' MitoPedia: [[International Union of Pure and Applied Chemistry, IUPAC |100 years of IUPAC]]''' - towards a '''common language'''. | |||
[[Image:O2k-brief.png|60px|link=http://wiki.oroboros.at/index.php/O2k-brief|O2k-brief]] '''''Blood Cells- High-Resolution FluoRespirometry and kinetics''''' - [http://wiki.oroboros.at/index.php/Orrico_2018_Free_Radic_Biol_Med Orrico 2018 Free Radic Biol Med]''' | |||
<br/> | |||
<br/> | <br/> | ||
[[ | <big><big>'''NeuroVive enters commercial partnership with Oroboros Instruments on mitochondrial medicine research compounds'''</big></big> | ||
[[File:NeuroVive.png|right|200px|link=http://wiki.oroboros.at/index.php/NeuroVive]] | |||
''' [ | ''NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has entered into an exclusive agreement to license and supply two of its first generation of succinate/malonate prodrugs as research tool compounds to Oroboros Instruments, a global supplier of mitochondrial research technologies. | ||
NeuroVive have agreed to provide, at scale, two research compounds, originating from its NVP015 program, on an exclusive basis to Oroboros. Depending on bulk quantities supplied, the agreement has the potential to generate revenue to NeuroVive in the range of €10,000-50,000 per annum. Oroboros will commercialize and distribute the compounds after completed internal evaluation. Oroboros Instruments are world leading in the development and supply of analytical instrumentation and reagents for use in mitochondrial biology and mitochondrial medicine research and development. | |||
Eskil Elmér, CSO NeuroVive commented “We are excited to be able to supply compounds from our succinate prodrug family designated exclusively for research use to the scientific community. Oroboros Instruments is the perfect partner to reach thousands of scientists in the field. These cell-permeable compounds, that can stimulate and inhibit Complex II of the respiratory electron transfer system in intact cells, will expand the toolbox for evaluating the role of mitochondria in disease. NeuroVive revenues will be modest but the primary value is that this is part of our mission to promote the development of mitochondrial medicine research.”'' | |||
* ''More details:'' [http://publish.ne.cision.com/v2.0/Release/ViewReleaseHtml/3E27A077A0FDB7B5 ViewReleaseHtml]''' oder link zu unserer Website? | |||
* Expected distribution date: ## | |||
: '''Order here:''' [mailto:instruments@oroboros.at instruments@oroboros.at] | |||
<br/> | |||
</div> | </div> | ||
Latest revision as of 16:15, 11 March 2019
Oroboros News
New in MitoPedia: 100 years of IUPAC - towards a common language.
Blood Cells- High-Resolution FluoRespirometry and kinetics - Orrico 2018 Free Radic Biol Med
NeuroVive enters commercial partnership with Oroboros Instruments on mitochondrial medicine research compounds
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has entered into an exclusive agreement to license and supply two of its first generation of succinate/malonate prodrugs as research tool compounds to Oroboros Instruments, a global supplier of mitochondrial research technologies.
NeuroVive have agreed to provide, at scale, two research compounds, originating from its NVP015 program, on an exclusive basis to Oroboros. Depending on bulk quantities supplied, the agreement has the potential to generate revenue to NeuroVive in the range of €10,000-50,000 per annum. Oroboros will commercialize and distribute the compounds after completed internal evaluation. Oroboros Instruments are world leading in the development and supply of analytical instrumentation and reagents for use in mitochondrial biology and mitochondrial medicine research and development.
Eskil Elmér, CSO NeuroVive commented “We are excited to be able to supply compounds from our succinate prodrug family designated exclusively for research use to the scientific community. Oroboros Instruments is the perfect partner to reach thousands of scientists in the field. These cell-permeable compounds, that can stimulate and inhibit Complex II of the respiratory electron transfer system in intact cells, will expand the toolbox for evaluating the role of mitochondria in disease. NeuroVive revenues will be modest but the primary value is that this is part of our mission to promote the development of mitochondrial medicine research.”
- More details: ViewReleaseHtml oder link zu unserer Website?
- Expected distribution date: ##
- Order here: instruments@oroboros.at
